Research and Development Investment: AstraZeneca PLC vs Viridian Therapeutics, Inc.

AstraZeneca vs. Viridian: R&D Investment Trends Unveiled

__timestampAstraZeneca PLCViridian Therapeutics, Inc.
Wednesday, January 1, 20145579000000293000
Thursday, January 1, 201559970000001002000
Friday, January 1, 20165890000000888000
Sunday, January 1, 2017575700000019623000
Monday, January 1, 2018593200000030421000
Tuesday, January 1, 2019595800000034794000
Wednesday, January 1, 2020599100000028304000
Friday, January 1, 2021973600000056886000
Saturday, January 1, 20229762000000100894000
Sunday, January 1, 202310935000000159765000
Monday, January 1, 202413583000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of R&D Investment: AstraZeneca vs. Viridian

In the ever-evolving pharmaceutical landscape, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, AstraZeneca PLC has consistently demonstrated its commitment to R&D, with expenditures increasing by nearly 96% from 2014 to 2023. In contrast, Viridian Therapeutics, Inc., a smaller player, has shown a remarkable growth trajectory, with R&D spending skyrocketing by over 54,000% during the same period.

AstraZeneca's robust investment strategy, peaking at approximately $10.9 billion in 2023, underscores its focus on pioneering treatments and maintaining its competitive edge. Meanwhile, Viridian's exponential growth, reaching around $160 million in 2023, highlights its aggressive push to innovate and expand its therapeutic portfolio. This comparison not only reflects the diverse strategies of these companies but also illustrates the dynamic nature of the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025